◐ V-Series Protocol
Skin renewal and hair density
Every component is individually sourced, third-party verified, and dispensed within physician supervision. Tap any compound for its full clinical reference.
A dermatological protocol pairing two synergistic peptides to address the two primary mechanisms of visible skin aging: chronic inflammation and dermal matrix breakdown. KPV calms the inflammatory cascade at the nuclear level; GHK-Cu rebuilds the structural matrix. The result is measurable improvement in clarity, density, and tone. For patients who have come across pre-compounded dermal-repair blends - KPV layered onto a GHK-Cu / BPC-157 / TB-500 base, sold direct-to-consumer in the medspa market - V-06 is the supervised clinical version: the same anti-inflammatory + matrix-synthesis logic, scoped to the dermatological indication, allocated and monitored within a physician workflow.
CLINICAL INDICATION: Patients with chronic facial redness, post-inflammatory pigmentation, premature dermal aging, or recurrent inflammatory skin conditions
GHK-Cu carries the strongest human clinical evidence base of any peptide in V-06. KPV has well-characterised preclinical mechanism but no controlled human trials to date - disclosed honestly below.
In a randomized, controlled multi-center trial of chronic diabetic foot ulcers, topical GHK-Cu hydrogel achieved 87.5–88% complete closure compared with 30–34% in the standard-care control arm. Median time to closure was 6.2 weeks versus over 11 weeks for control. Localized infection rates were also significantly reduced.
Mulder GD, Patt LM, et al. (1994). Enhanced healing of ulcers in patients with diabetes by topical application of glycyl-L-histidyl-L-lysine copper complex. Wound Repair and Regeneration, 2(4), 259–269.
Endogenous plasma GHK-Cu declines linearly across the human lifespan: approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60 - a ~60% reduction in the molecule responsible for triggering tissue repair signalling.
Pickart L (2008). The regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Skin Pharmacology and Physiology, 21(5), 245–255.
Broad Institute Connectivity Map (cMap) computational analysis showed GHK-Cu significantly modulates the expression of approximately 4,192 human genes, with the regulation pattern shifting tissue toward a younger homeostatic profile. Upregulates antioxidant systems and neurotrophic factors; downregulates pro-inflammatory networks.
Campbell JD, Pickart L, et al. (2012). A GHK-Cu-mimetic gene expression profile correlates with better survival in lung cancer patients and identifies pathways of tissue remodeling. Genome Medicine, 4(12), 99.
In human fibroblast cultures, micro-molar doses of GHK-Cu drive dose-dependent synthesis of Type I and Type III collagen, elastin, and glycosaminoglycans, while balancing matrix metalloproteinase (MMP) and TIMP activity to favour clean tissue remodelling over fibrotic scarring.
Maquart FX, Pickart L, et al. (1988). Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺. FEBS Letters, 238(2), 343–346.
In animal models of dextran sulfate sodium (DSS)-induced colitis, KPV reduced mucosal inflammation, restored epithelial tight-junction integrity, and prevented colon shortening through MC1R-mediated inhibition of NF-κB translocation. Mechanism is well characterised; human clinical translation remains pending.
Kannengiesser V, et al. (2008). Melanocortin-derived tripeptide KPV reduces α-MSH-induced pigmentary responses but preserves anti-inflammatory actions in intestinal epithelial cells. Inflammatory Bowel Diseases, 14(3), 324–331; Dalmasso G, et al. (2006). Journal of Biological Chemistry, 281(39), 28873–28884.
Evidence tiers (Human RCT > Human Biochemistry > Genomic/Mechanistic > In Vitro > Preclinical) reflect translational distance. Vivre presents the human data prominently and flags preclinical evidence explicitly so patients can weigh it honestly.
Dermatological optimization protocol combining KPV - an α-MSH-derived tripeptide that inhibits NF-κB signaling and reduces pro-inflammatory cytokine production - with GHK-Cu, a copper-binding tripeptide that drives collagen and elastin synthesis through fibroblast activation. The pairing addresses both inflammatory and structural drivers of dermal aging in parallel.
Most aesthetic interventions address one of two problems: inflammation OR structural breakdown. V-06 addresses both. KPV silences the inflammatory signal that degrades collagen as it forms; GHK-Cu drives the matrix synthesis that gives skin its density and clarity. Topical formulations cannot reach the depth or sustained concentration that systemic dosing achieves - V-06 is positioned as a complement to good topical practice, not a replacement.
| What's in the box | Specification | Per month |
|---|---|---|
| KPV | 10mg vial · 2 vials typical monthly supply | 2× |
| GHK-Cu | 10mg vial · 2 vials typical monthly supply | 2× |
Dermatological - GHK-Cu, V-06
These protocols support skin elasticity, clarity, and dermal repair. Assessment here leans on dermatological evaluation and imaging more than bloodwork, with inflammation tracked as a supporting signal.
Incremental approach. Conservative, often topical or low-dose protocols assessed visually and by imaging over a defined window before extending.
Educational only - not medical advice or a dosing instruction. Your physician orders the tests, sets your dose, interprets results, and decides if a protocol is right for you. See the Informed Consent & Disclaimer for full terms.
| Biomarker | Why It's Monitored | Baseline | Cadence |
|---|---|---|---|
| hs-CRP | Systemic inflammatory contribution to skin | Yes | Baseline + checkpoint |
| Standardised skin assessment | Dermal clarity/density tracking | Yes | Wk 4, 8, 12 |
| Inflammatory markers (as indicated) | Where an inflammatory skin component is present | Optional | If indicated |
| Tolerability log | Local/systemic tolerability tracking | Yes | Ongoing |
Randomized, controlled, multi-center trial in patients with chronic non-healing diabetic foot ulcers. Topical GHK-Cu hydrogel achieved 87.5–88% complete wound closure compared with 30–34% in the standard-care control arm. Median time to complete closure was approximately 6.2 weeks for the GHK-Cu group versus more than 11 weeks for control. Localized infection rates were also significantly reduced. This remains one of the strongest human RCT data points for any peptide in the regenerative category.
View on publisher ↗Landmark in vitro study in human dermal fibroblast cultures. Demonstrated that micromolar GHK-Cu drives dose-dependent synthesis of Type I and Type III collagen, elastin, and glycosaminoglycans, and balances matrix metalloproteinase (MMP) and TIMP activity to favour clean tissue remodelling over fibrotic scarring. The mechanistic basis for GHK-Cu’s use in dermal-architecture protocols.
View on publisher ↗Broad Institute Connectivity Map (cMap) computational analysis quantified that GHK-Cu modulates expression of approximately 4,192 human genes, shifting tissue toward a younger homeostatic profile. Upregulates antioxidant systems, neurotrophic factors, and metabolic clearance pathways; downregulates pro-inflammatory networks. The genomic-systems basis for why GHK-Cu has effects across multiple tissue beds.
View on publisher ↗Review of the GHK-Cu literature including gene-expression profiling work showing modulation of multiple tissue-repair-related genes, with effects on collagen synthesis, matrix metalloproteinase regulation, and inflammatory signalling. Strongest evidence is in dermal/topical applications; systemic use is less characterised in controlled trials.
View on publisher ↗In vitro and ex vivo dermal study (human keratinocytes). Demonstrated that GHK-Cu maintains the stemness of basal keratinocytes and integrin expressions, mobilising intrinsic progenitor cell lines to migrate toward sites of acute structural degradation. Provides the cellular basis for GHK-Cu’s role in dermal renewal beyond fibroblast-mediated matrix synthesis.
View on publisher ↗Mechanistic review documenting GHK’s role as a non-toxic copper chaperone delivering Cu(II) into cells without triggering radical-induced lipid peroxidation. Cytochrome c Oxidase (Complex IV) of the mitochondrial electron transport chain requires copper at its catalytic centres, so adequate copper delivery is upstream of ATP synthesis. Genomic profiling confirmed upregulation of PGC-1α pathway genes (mitochondrial biogenesis). The often-quoted "67% ATP increase" originates from localised in vitro stress-condition data and should be framed as "restoration of defective ATP production under cellular stress" rather than a baseline boost - Vivre presents it this way honestly.
View on publisher ↗Preclinical · Animal Models. In rat coronary-ligation experiments, pre-treatment with GHK-Cu reduced infarct size and preserved cardiac function via upregulation of bFGF and VEGF (angiogenesis). In rodent diabetic nephropathy models, GHK-Cu downregulated TGF-β (the primary fibrosis driver), reducing mesangial expansion, basement membrane thickening, and extracellular matrix accumulation in the renal filtering apparatus. Note: these are animal-model data and have not been translated to human cardiology or nephrology RCTs - Vivre cites them as mechanistic support for the tissue-remodelling case, not as human clinical efficacy.
View on publisher ↗Preclinical · Rodent and In Vitro. Genomic data verify that GHK-Cu downregulates the amyloid precursor protein (APP) gene and upregulates neurotrophic pathways (NGF and BDNF). Animal-model evidence indicates blood-brain-barrier permeability and neuroprotective effects against beta-amyloid and oxidative-stress insults. The frequently-quoted "300% NGF increase" originates from rodent / in-vitro data and is presented here as preclinical signal, not as human cognitive-clinical evidence - which does not yet exist in controlled RCT form for GHK-Cu.
View on publisher ↗Preclinical · In Vitro + Mouse Alopecia Model. The novel contribution of the paper is a bio-based ionic liquid microemulsion (CaT-ME, made from L-carnitine and tartaric acid) as a topical delivery vehicle - not GHK-Cu efficacy per se. Loaded with GHK-Cu, the system improved porcine-skin permeation 3.18× vs PBS in vitro, and in a C57BL/6 mouse alopecia model, GHK-Cu/CaT-ME entered the anagen (growth) phase at day 6 versus day 9 for 5% topical minoxidil - a head-to-head win against the FDA-approved comparator in a mouse model. Mechanism work documented upregulation of VEGF and HGF (follicular angiogenic factors), CD31 (vascular endothelium), Ki67 (proliferation), β-catenin and p-GSK3β (Wnt pathway activation), and Ldha (hair follicle stem cell activation enzyme). The paper reinforces three mechanisms that anchor GHK-Cu's hair-growth thesis: fibroblast-stimulated VEGF, TGF-β suppression preventing premature anagen→catagen, and dermal papilla cell proliferation. Important methodology framing: preclinical (mouse + ex vivo porcine skin) only - no human RCT. The route tested is topical microemulsion, not the injectable route Vivre offers - the shared element is the GHK-Cu mechanism, not the delivery vehicle. Two co-author affiliations (Shenzhen Shinehigh Innovation Technology, Harbin Voolga Technology) have commercial interests in the technology, and the GHK-Cu raw material was supplied by a related Shenzhen entity. The authors declare no conflict of interest per ICMJE rules, but the originating-group + commercial-affiliation pattern is flagged here per Vivre's standard discipline (same approach applied to Epithalon and other single-group preclinical work).
View on publisher ↗Preclinical study (in vitro intestinal epithelial cell lines + DSS-colitis mouse model). Identified that KPV is taken up by the intestinal peptide transporter PepT1 and produces dose-dependent suppression of NF-κB signalling and pro-inflammatory cytokine secretion (IL-1β, TNF-α pathway). Established the mechanistic basis for KPV use in IBD-adjacent contexts. The study is preclinical - cell lines and mice, not humans - and no controlled human RCT of KPV in IBD has subsequently been published.
View on publisher ↗Preclinical · Animal Model. In multi-center models of acute and chronic colitis (dextran sulfate sodium-induced), oral or systemic KPV demonstrated profound therapeutic efficacy. Histological evaluation confirmed reduced mucosal inflammation, restored epithelial tight-junction barrier integrity, prevention of weight loss and colon shortening. Critically, the work documented that KPV preserves the anti-inflammatory action of larger melanocortin peptides without triggering the pigmentary side effects associated with full-length α-MSH - a key selectivity finding for clinical translation.
View on publisher ↗In-vitro study in immortalised human bronchial epithelial cells. KPV produced dose-dependent inhibition of TNF-α and RSV-evoked NF-κB activation, MMP-9 activity, and IL-8 / eotaxin secretion. Suggested a mechanistic role for KPV in airway-inflammation contexts. Findings remain at the cell-line level; no controlled human RCT in airway disease has been conducted.
View on publisher ↗Preclinical · Rodent Models. In rodent protocols using lipopolysaccharide (LPS)-induced neuroinflammation, melanocortin-derived tripeptides including KPV crossed the blood-brain barrier and damped microglial over-activation, safeguarding neighbouring neurons from reactive oxygen species and cytokine-induced apoptosis. Provides mechanistic support for the broader thesis that NF-κB-inhibiting tripeptides have effects in tissue beds beyond the gut. Animal model data only - no human translation yet.
View on publisher ↗The Audit is complimentary for the Batch 001 cohort. Your physician will review your data, confirm protocol suitability, and initiate the V-06 allocation if appropriate.
Are you 18 years of age or older?